Clinicopathological Features of NSCLC Patients Associated With the Chromosome 2p (EML4-ALK) (ALK)
|ClinicalTrials.gov Identifier: NCT01662635|
Recruitment Status : Completed
First Posted : August 10, 2012
Results First Posted : November 21, 2014
Last Update Posted : October 14, 2016
|Condition or disease|
|Non Small-cell Lung Cancer|
Lung adenocarcinoma studies. The only inclusion criterion was the availability of tissue for biomarker studies. To identify ALK rearrangements, fluorescence in situ hybridization (FISH) studies were performed on 3 to 4 mm thick paraffin sections from NSCLCs. The commercially labeled Vysis LSI ALK Dual Color (split-apart), break-apart rearrangement probe (Abbott Molecular, Abbott Park, IL) was used to detect any rearrangement involving the ALK gene. The probe hybridizes to band 2p23, on either side of the ALK gene breakpoint. Criteria for probe signal interpretation in at least 200 interphase nuclei were as follow: 1) separated green and orange signals or single red signals identified cells with rearranged ALK; 2) overlapping of red and green signals (yellowish) indicated cells in which ALK was not rearranged.
FISH-positive samples for ALK rearrangement were defined as having cells with a clearly separated pair of probe signals, or with >15% of cells having loss of the 5´(centromeric) probe. The higher threshold for loss is necessary because parts of probes can be lost during sectioning.
The aim of our study is to evaluate the utility of IHC with 5A4 and RT-qPCR in the detection of ALK rearrangements in NSCLC compared with the current method of choice, FISH. Further, we report on the demographics, and clinicopathologic features of ALK-rearranged NSCLC in a Latin-American population.
Clinical details of these patients were included in a database. Further results will be analyzed with the program SPSS17
|Study Type :||Observational|
|Actual Enrollment :||230 participants|
|Official Title:||CLINICOPATHOLOGICAL FEATURES OF NON-SMALL CELL LUNG CANCER PATIENTS ASSOCIATED WITH THE CHOROMOSOME 2p (EML4-ALK) INVERSION IN MEXICAN POPULATION.|
|Study Start Date :||February 2011|
|Primary Completion Date :||September 2014|
|Study Completion Date :||September 2014|
We reviewed 230 consecutive cases of NSCLC that were retrieved from oncologic molecular laboratory and diagnostic pathology unit at the Instituto Nacional de Cancerologia, Mexico city, between 2011 and 2014. Samples were sent to the unit of pathological anatomy, a Pathologist confirmed the histologic diagnosis. The only inclusion criterion was the availability of tissue for biomarker studies. Clinical and pathologic details of these patients were included in a database, obtained from medical records.
For ALK fusion testing, we applied dual-color, break-apart FISH, RT-qPCR, and immunohistochemistry. Interpretation of the results was done in double-blind manner without knowing the results by other methods.
- FISH, IHC, RT-qPCR Comparison [ Time Frame: TWO YEARS ]200 samples underwent FISH, from them 63 underwent IHC and 48 RT-qPCR.
Biospecimen Retention: Samples With DNA
FISH studies were performed in 3-mm to 4-mm thick paraffin sections from 230 NSCLCs and 1 ALCL specimen with t(2;5) that was used as a positive control for the break-apart detection.
48 patients were analyzed for the presence of EML4-ALK gene fusion variants using the RNA from frozen tissue sections
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01662635
|Instituto Nacional de Cancerologia|
|Mexico, DF, Mexico, 14080|
|Principal Investigator:||Oscar Arrieta, MD||Instituto de Cancerología|